Mayo Clinic in Arizona

Running trials

• Not yet recruiting

  A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)

  NCT07906665· Phase 1· Source

• Not yet recruiting

  Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial

  NCT07206589· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Source

• Not yet recruiting

  Strengthening Teen Brain Resilience Using Music Intervention to Improve Radiation Induced Cognitive Decline for Adolescents Undergoing Radiation Therapy for Cancer Treatment

  NCT07729384· Source

• Recruiting

  Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors

  NCT07856394· Source

• Recruiting

  Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

  NCT07708961· Phase 2· Source

• Recruiting

  Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  NCT07805954· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

  NCT07498426· Phase 3· Source

• Recruiting

  A Phase 1 Study of the Safety and Tolerability of CTX-10726

  NCT07419841· Phase 1· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07450859· Phase 2· Source

• Recruiting

  A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  NCT07277413· Phase 1· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change

  NCT07110337· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

  NCT07110454· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

  NCT07226856· Phase 2· Source

• Recruiting

  Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

  NCT07188532· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Source

• Recruiting

  Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

  NCT06525766· Phase 2· Source

• Recruiting

  Q702 for the Treatment of Patients With Hematologic Malignancies

  NCT06712810· Phase 1· Source

• Recruiting

  Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

  NCT07025369· Phase 2· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Source

• Recruiting

  Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

  NCT07091864· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Source

• Recruiting

  Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

  NCT06972056· Phase 4· Source

• Recruiting

  Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

  NCT06464926· Source

• Recruiting

  REgulatory T Cell Therapy to Achieve Immunosuppression REduction

  NCT06552169· Phase 2· Source

• Recruiting

  Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

  NCT06668493· Phase 1/2· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Source

• Recruiting

  Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

  NCT06635980· Phase 2· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Source

• Recruiting

  Treatment of Moderate to Severe Refractory Crohn's Disease

  NCT06721962· Phase 1/2· Source

• Recruiting

  A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  NCT06892548· Phase 1/2· Source

• Recruiting

  BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

  NCT06854003· Phase 2· Source

• Enrolling by invitation

  The DIAGNOSE CTE Research Project-II

  NCT06860828· Source

• Recruiting

  Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  NCT06834373· Phase 2· Source

• Recruiting

  Pulmonary Rehabilitation for Rural Patients With COPD

  NCT06847061· Source

• Active, not recruiting

  A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06356571· Phase 2· Source

• Recruiting

  Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

  NCT06797193· Source

Showing 50 of 237.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer9 recruiting
• Multiple myeloma9 recruiting
• Colorectal cancer8 recruiting
• Pancreatic cancer8 recruiting
• Childhood cancers7 recruiting
• Prostate cancer7 recruiting
• Bladder cancer6 recruiting
• Gastric and oesophageal cancer6 recruiting
• Sarcoma6 recruiting
• Acute myeloid leukaemia5 recruiting
• Kidney cancer5 recruiting
• Myelodysplastic syndromes5 recruiting
• Ovarian cancer5 recruiting
• Endometrial cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Melanoma4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Crohn's disease3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Epilepsy3 recruiting
• Follicular lymphoma3 recruiting
• Glioblastoma3 recruiting
• Metastatic breast cancer3 recruiting
• Migraine3 recruiting
• Neuroendocrine tumours3 recruiting
• Ulcerative colitis3 recruiting
• Alzheimer disease2 recruiting
• Amyloidosis2 recruiting
• Chronic myeloid leukaemia2 recruiting
• COPD2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• Mesothelioma2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Obesity2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Lewy body dementia1 recruiting
• Long COVID and ME/CFS1 recruiting
• Mantle cell lymphoma1 recruiting
• Osteoporosis1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06790966· Phase 3· Source

• Terminated

  NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

  NCT06420349· Phase 1· Source

• Completed

  Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

  NCT05730712· Phase 2· Source

• Terminated

  CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

  NCT05689021· Phase 2· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Source

• Completed

  Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

  NCT06126796· Source

• Completed

  A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

  NCT06151717· Source

• Completed

  Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

  NCT06037863· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Source

• Completed

  Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning

  NCT05979883· Source

• Completed

  Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

  NCT05557162· Source

• Completed

  Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study

  NCT06063603· Source

• Completed

  A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

  NCT05712356· Phase 2· Source

• Completed

  Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

  NCT05593328· Phase 2· Source

• Terminated

  A Study of Remote Electrical Neuromodulation for Acute Procedural Pain

  NCT05730556· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Source

• Terminated

  Testing Obeticholic Acid for Familial Adenomatous Polyposis

  NCT05223036· Phase 2· Source

• Completed

  A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

  NCT05376800· Phase 1· Source

• Terminated

  Oral AMXT 1501 Dicaprate in Combination With IV DFMO

  NCT05500508· Phase 1/2· Source

• Completed

  Study of DF9001 in Patients With Advanced Solid Tumors

  NCT05597839· Phase 1/2· Source

• Terminated

  E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

  NCT05388877· Phase 1· Source

• Completed

  IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

  NCT05372003· Early phase 1· Source

• Completed

  RNS System NAUTILUS Study

  NCT05147571· Source

• Completed

  A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

  NCT05442047· Phase 2· Source

• Completed

  Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

  NCT05945290· Source

• Completed

  Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

  NCT05854992· Source

• Terminated

  Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

  NCT05288062· Phase 2· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Terminated

  Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  NCT05103904· Phase 2· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Source

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Phase 1· Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Phase 2· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Source

• Terminated

  Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate Cancer

  NCT06016504· Source

• Completed

  Regulation of Muscle Protein Phenotype in Humans With Obesity

  NCT04700800· Source

• Completed

  Development of an EEG Diagnostic for Alzheimer's Disease

  NCT04954183· Source

• Terminated

  Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

  NCT04805788· Phase 2· Source

• Completed

  Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study

  NCT05053100· Source

• Terminated

  A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  NCT04577963· Phase 1/2· Source

• Completed

  Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

  NCT03961945· Source

• Completed

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· Phase 1· Source

• Terminated

  Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· Phase 2· Source

• Completed

  RegoNivo vs Standard of Care Chemotherapy in AGOC

  NCT04879368· Phase 3· Source

• Terminated

  A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

  NCT04837131· Phase 2· Source

• Terminated

  A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04776018· Phase 1/2· Source

• Completed

  Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

  NCT04499924· Phase 2/3· Source

• Terminated

  PF-07284892 in Participants With Advanced Solid Tumors

  NCT04800822· Phase 1· Source

• Terminated

  CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  NCT04695977· Phase 2/3· Source

• Terminated

  GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

  NCT04100135· Source

Showing 50 of 115.

Trial sites

• 8400772 - Mayo Clinic Arizona1 trial
• Arizona Mayo Clinic1 trial
• Banner Alzheimer's Institute (BAI) and Mayo Clinic Arizona1 trial
• Mayo Clinic - Arizona87 trials
• Mayo Clinic Arizona (adults)1 trial
• Mayo Clinic Arizona /ID# 2149571 trial
• Mayo Clinic Arizona /ID# 2185501 trial
• Mayo Clinic Arizona /ID# 2514051 trial
• Mayo Clinic Arizona /ID# 2558581 trial
• Mayo Clinic Arizona /ID# 2607991 trial
• Mayo Clinic Arizona /ID# 2626101 trial
• Mayo Clinic - Arizona (Site 0090)1 trial
• Mayo Clinic Arizona - Site #3631 trial
• Mayo Clinic in Arizona9 trials
• Mayo Clinic in Arizona - Phoenix9 trials
• Mayo Clinic in Arizona - Phoenix Campus1 trial
• Mayo Clinic in Arizona - Phoenix (Site 0043)1 trial
• Mayo Clinic in Arizona - Phoenix (Site 0044)1 trial
• Mayo Clinic in Arizona - Phoenix (Site 0147)1 trial
• Mayo Clinic in Arizona - Phoenix (Site 1094)1 trial
• Mayo Clinic in Arizona - Phoenix (Site 3554)1 trial
• Mayo Clinic in Arizona - Phoenix- Site Number : 84000051 trial
• Mayo Clinic in Arizona - Phoenix- Site Number : 84000581 trial
• Mayo Clinic - Arizona34 trials
• Mayo Clinic Arizona - PPDS1 trial
• Mayo Clinic Arizona, Scottsdale, AZ1 trial
• Mayo Clinic in Arizona193 trials
• Mayo Clinic in Arizona - Scottsdale5 trials
• Mayo Clinic - Scottsdale Arizona1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation72 works · 1 trial
• Prostate cancer65 works · 30 trials
• Asthma46 works · 0 trials
• Multiple myeloma45 works · 31 trials
• Migraine42 works · 8 trials
• Pancreatic cancer38 works · 13 trials
• Melanoma37 works · 13 trials
• Bladder cancer27 works · 22 trials
• Glioblastoma24 works · 16 trials
• Neuroendocrine tumours20 works · 4 trials
• Hypertrophic cardiomyopathy17 works · 0 trials
• Myeloproliferative neoplasms11 works · 9 trials
• Chronic lymphocytic leukaemia9 works · 10 trials
• Follicular lymphoma6 works · 6 trials
• Primary biliary cholangitis4 works · 0 trials